Keywords: update, bristol-myers, squibb, looks, oncology, come-back, 430m

UPDATE: Bristol-Myers Squibb looks to oncology come-back with $430M bid for Adnexus

Article | 01 October 2007

Print This

Bristol-Myers Squibb, the US drug major that once dominated the oncology market with products such as Taxol (paclitaxel) is making ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in